



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Zoonotic tuberculosis in Africa: challenges and ways forward

Outbreaks of Ebola virus, Middle East respiratory syndrome coronavirus, and Zika virus have highlighted the importance of the One Health initiative, and have challenged the field of public health to think about disease management and surveillance within multispecies host-pathogen ecosystems. The threat of zoonotic tuberculosis presents another case in point: millions of people exposed to unregulated mobile livestock—especially in Africa—are at risk of zoonotic tuberculosis from a range of mycobacterium species from these animals.¹⁻⁵ However, information about the genetic specifications, prevalence, or transmission of zoonotic tuberculosis outside industrialised farms or, more generally, the contribution of animals to human tuberculosis incidence is inadequate.¹⁻⁶ Successful tuberculosis control efforts focused on *Mycobacterium tuberculosis* have resulted in increasing zoonotic tuberculosis cases, and this increase is expected to continue as *M tuberculosis* nears elimination.^{3,7}

After a patient is diagnosed with tuberculosis, molecular typing can determine the strain, optimise treatment, and identify the source of infection.² However, although zoonotic tuberculosis might contribute to as much as 10% of the global human tuberculosis burden,¹⁻³ this type of testing remains unavailable in Africa.⁴⁻⁶

Zoonotic tuberculosis is essentially a neglected tropical disease. Human *Mycobacterium bovis* infection, for example, is found almost exclusively in low-income

countries and minority and migrant populations within high-income countries.¹⁻⁷ Small-scale studies⁸⁻¹⁰ have detected *M bovis* and *M tuberculosis* in rural camel and cattle herds, and in various wildlife species in Africa. Researchers have hypothesised that mycobacterium species other than *M bovis* might be responsible for the high rates of extrapulmonary tuberculosis cases in Ethiopia,⁶ and in another study,¹¹ up to 10% of camels sampled in pastoralist regions of Ethiopia were reactive to *Mycobacterium avium*.

And yet, in Africa, robust datasets and disease surveillance for zoonotic tuberculosis, other than within industrialised farms and hospitals, are non-existent. This absence is largely because zoonotic tuberculosis remains one of the most difficult pathogens to detect: testing technologies are prohibitively expensive and unreliable without state of the art laboratories and cold chains, there are no known biomarkers of mycobacterium species in milk samples, and blood tests require discrimination between an active tuberculosis infection and mere exposure.^{1,2}

Despite these challenges, genetic typing of tuberculosis in livestock, livestock products, and people at high risk of infection are essential for tuberculosis control. Although some studies⁶ report that *M bovis* and *M tuberculosis* are clinically indistinct, other studies^{7,11} attribute high rates of extrapulmonary tuberculosis in Africa to either animal exposures or *M bovis* infection. Regardless of clinical presentation, *M bovis* is intrinsically resistant to pyrazinamide, a key first-line anti-tuberculosis drug, necessitating a 9 month instead of a 6 month treatment duration and alternative medications.¹² Furthermore, in some cases, *M bovis* is now resistant to streptomycin too, which is likely to contribute to its high mortality.^{7,13} The increase in *M bovis* drug resistance might result from the overuse of antibiotics in livestock husbandry, and could foreshadow future challenges in human tuberculosis treatment and control.

However, most policy roadmaps, disease surveillance systems, clinical diagnostics, and food safety mechanisms fail to take into account how the people most at risk of zoonotic tuberculosis interact with and consume mobile livestock and their products. For example, millions of people in east and north Africa



regularly consume unpasteurised camel milk, for the purpose of food and medical therapeutics. Pasteurisation changes both the taste and perceived bodily effects of this milk, and many people fear that incorporation of large mobile livestock into industrialised farms could also decimate their economic and cultural value. Furthermore, livestock in Africa are frequently herded outside industrialised farms, slaughtered outside regulated abattoirs, exchanged within informal livestock and food markets, transported transnationally across huge geographical spaces, and treated outside well equipped veterinary health facilities.

Zoonotic tuberculosis is a global problem. People infected with zoonotic tuberculosis in Africa have presented with active tuberculosis in the USA,¹³ and as refugee and migrant flows continue, these cases will undoubtedly increase. Researchers have been aware of zoonotic tuberculosis for decades, especially among mobile and unregulated livestock herds in Africa, and WHO's Strategic and Technical Advisory Group meeting in 2016 called for improved zoonotic tuberculosis surveillance, diagnostic tools, and global awareness.¹⁴ However, it remains to be seen whether the global health community will act now on zoonotic tuberculosis control, or if investments will only be made once the disease threatens populations outside the African continent.

Rapid and affordable field diagnostics and disease surveillance for zoonotic tuberculosis are desperately needed. These tools will require new investments in research on prevalence in human beings and livestock at highest risk, and in development of innovative field-ready zoonotic tuberculosis tests; coordination between local, national, global, and private stakeholders; and new and innovative disease surveillance mechanisms responsive to the lives, economies, and diets of pastoralists and other rural livestock holders in Africa.

*Lauren Carruth, Amira A Roess,
Yitagele Tefere Mekonnen, Simenew Keskes Melaku,
Mark Nichter, Mo Salman

School of International Service, American University, Washington, DC 20016, USA (LC); Department of Global Health, Milken Institute School of Public Health, George Washington University, DC, USA (AAR); College of Veterinary Medicine, Haramaya University, Haramaya, Ethiopia (YTM); College of Agriculture and Rural Development, Dilla University, Dilla, Ethiopia (SKM); School of Anthropology, Department of Family and Community Medicine, and College of Public Health, The University of Arizona, Tucson, AZ, USA (MN); and Animal Population Health Institute, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA (MS)
lcarruth@american.edu

We declare no competing interests.

- 1 US Centers for Disease Control and Prevention. *Mycobacterium bovis* (bovine tuberculosis) in humans. 2011. <http://www.cdc.gov/tb/publications/factsheets/general/mbovis.pdf> (accessed Dec 6, 2015).
- 2 Thoen CO, Steele JH, Kaneene JB. Zoonotic tuberculosis: *Mycobacterium bovis* and other pathogenic mycobacteria. Oxford: John Wiley & Sons, 2014.
- 3 Etter E, Donado P, Jori F, Caron A, Goutard F, Roger F. Risk analysis and bovine tuberculosis, a re-emerging zoonosis. *Ann N Y Acad Sci* 2006; **1081**: 61–73.
- 4 Cosivi O, Grange JM, Daborn CJ, et al. Zoonotic tuberculosis due to *Mycobacterium bovis* in developing countries. *Emerg Infect Dis* 1998; **4**: 59–70.
- 5 Ayele WY, Neill SD, Zinsstag J, Weiss MG, Pavlik I. Bovine tuberculosis: an old disease but a new threat to Africa. *Int J Tuberc Lung Dis* 2004; **8**: 924–37.
- 6 Berg S, Schelling E, Hailu E, et al. Investigation of the high rates of extrapulmonary tuberculosis in Ethiopia reveals no single driving factor and minimal evidence for zoonotic transmission of *Mycobacterium bovis* infection. *BMC Infect Dis* 2015; **15**: 112.
- 7 Rodwell TC, Moore M, Moser KS, Brodine SK, Strathdee SA. Tuberculosis from *Mycobacterium bovis* in binational communities, United States. *Emerg Infect Dis* 2008; **14**: 909–16.
- 8 Kudi AC, Bello A, Ndukum JA. Prevalence of bovine tuberculosis in camels in Northern Nigeria. *J Camel Pract Res* 2012; **19**: 81–86.
- 9 Moiane I, Machado A, Santos N, et al. Prevalence of bovine tuberculosis and risk factor assessment in cattle in rural livestock areas of Govuro District in the southeast of Mozambique. *PLoS One* 2014; **9**: e91527.
- 10 Renwick AR, White PC, Bengis RG. Bovine tuberculosis in southern African wildlife: a multi-species host–pathogen system. *Epidemiol Infect* 2007; **135**: 529–40.
- 11 Müller B, Dürr S, Alonso S, et al. Zoonotic *Mycobacterium bovis*-induced tuberculosis in humans. *Emerg Infect Dis* 2013; **19**: 899–908.
- 12 Bobadilla-del Valle M, Torres-González P, Cervera-Hernández ME, et al. Trends of *Mycobacterium bovis* isolation and first-line anti-tuberculosis drug susceptibility profile: a fifteen-year laboratory-based surveillance. *PLoS Negl Trop Dis* 2015; **9**: e0004124.
- 13 Rock RB, Sutherland WM, Baker C, Williams DN. Extrapulmonary tuberculosis among Somalis, Minnesota. *Emerg Infect Dis* 2006; **12**: 1434.
- 14 Green A. Experts recognise zoonotic TB. *Lancet Respir Med* 2016; **4**: 433.